$60,000 of NEUROCRINE BIOSCIENCES INC. lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy"
You can find more data on corporate lobbying on Quiver Quantitative.
NBIX Insider Trading Activity
NBIX insiders have traded $NBIX stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $NBIX stock by insiders over the last 6 months:
- KEVIN CHARLES GORMAN sold 106,322 shares for an estimated $13,440,280
- WILLIAM H RASTETTER sold 18,000 shares for an estimated $2,732,689
- GARY A LYONS sold 15,000 shares for an estimated $2,289,082
- GEORGE J MORROW sold 15,000 shares for an estimated $2,150,512
- LESLIE V NORWALK has made 0 purchases and 2 sales selling 6,190 shares for an estimated $945,701.
- ERIC BENEVICH (Chief Commercial Officer) sold 5,970 shares for an estimated $905,880
- DARIN LIPPOLDT (Chief Legal Officer) sold 4,376 shares for an estimated $698,615
- KYLE GANO (Chief Executive Officer) sold 300 shares for an estimated $42,591
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
NBIX Hedge Fund Activity
We have seen 340 institutional investors add shares of NBIX stock to their portfolio, and 264 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AQR CAPITAL MANAGEMENT LLC added 1,263,633 shares (+83.7%) to their portfolio in Q3 2025, for an estimated $177,388,800
- CITADEL ADVISORS LLC removed 1,255,836 shares (-61.3%) from their portfolio in Q3 2025, for an estimated $176,294,257
- THRIVENT FINANCIAL FOR LUTHERANS added 559,154 shares (+4426.8%) to their portfolio in Q3 2025, for an estimated $78,494,038
- JPMORGAN CHASE & CO added 468,405 shares (+11.0%) to their portfolio in Q3 2025, for an estimated $65,754,693
- LOS ANGELES CAPITAL MANAGEMENT LLC added 458,106 shares (+61.5%) to their portfolio in Q3 2025, for an estimated $64,308,920
- TWO SIGMA INVESTMENTS, LP added 347,565 shares (+inf%) to their portfolio in Q3 2025, for an estimated $48,791,174
- AXA S.A. removed 341,734 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $47,972,618
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
NBIX Analyst Ratings
Wall Street analysts have issued reports on $NBIX in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 01/08/2026
- HC Wainwright & Co. issued a "Buy" rating on 12/17/2025
- Stifel issued a "Buy" rating on 12/11/2025
- TD Cowen issued a "Buy" rating on 12/05/2025
- Canaccord Genuity issued a "Buy" rating on 10/29/2025
- Citigroup issued a "Buy" rating on 10/29/2025
- RBC Capital issued a "Outperform" rating on 10/29/2025
To track analyst ratings and price targets for NBIX, check out Quiver Quantitative's $NBIX forecast page.
NBIX Price Targets
Multiple analysts have issued price targets for $NBIX recently. We have seen 15 analysts offer price targets for $NBIX in the last 6 months, with a median target of $179.0.
Here are some recent targets:
- Danielle Brill from Truist Securities set a target price of $169.0 on 01/08/2026
- Jeffrey Hung from Morgan Stanley set a target price of $175.0 on 01/08/2026
- Andrew S. Fein from HC Wainwright & Co. set a target price of $198.0 on 12/17/2025
- Uy Ear from Mizuho set a target price of $175.0 on 12/12/2025
- Paul Matteis from Stifel set a target price of $188.0 on 12/11/2025
- Brian Abrahams from RBC Capital set a target price of $180.0 on 12/08/2025
- Phil Nadeau from TD Cowen set a target price of $200.0 on 12/05/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
